| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | YD Bio Limited: YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease | 1 | GlobeNewswire (USA) | ||
| 20.10. | YD Bio Limited: YD Bio and EG BioMed Partner with JoiiUp to Launch AI-Driven Cancer Risk Assessment for Corporate Wellness Programs | 1 | GlobeNewswire (USA) | ||
| 01.09. | YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 | 343 | GlobeNewswire (Europe) | TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 01.09. | YD Bio Limited reports 1H results | 1 | Seeking Alpha | ||
| YD BIO Aktie jetzt für 0€ handeln | |||||
| 11.08. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.08. | YD Bio launches nutrition products via physician partnership model | 2 | Investing.com | ||
| 28.07. | YD Bio launches pilot for cancer testing in British Columbia | - | Investing.com | ||
| 02.07. | YD Bio Limited: YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations | 608 | GlobeNewswire (Europe) | Taipei, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 01.05. | YD Bio Limited Reports Full Year 2025 Financial Results | 283 | GlobeNewswire (Europe) | TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 06.01. | YD Bio Limited: YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation-Driven AI Platforms for Cancer Diagnostics and Drug Development | 434 | GlobeNewswire (Europe) | Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 05.01. | YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap | 674 | GlobeNewswire (Europe) | Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 24.11.25 | YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics | 464 | GlobeNewswire (Europe) | Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |